厄贝沙坦对慢性心力衰竭患者的疗效观察

Therapeutic effect of irbesartan on patients with chronic heart failure

目的：观察厄贝沙坦对慢性心力衰竭（CHF）患者的治疗效果及安全性。方法：2004年6月～2007年6月我院心内科共收治CHF患者193例，入院后病人均以血管紧张素转换酶抑制剂（ACEI）、β受体阻滞剂、洋地黄类、利尿剂作常规抗心力衰竭治疗，对达到全剂量常规抗心力衰竭治疗的71例CHF患者，在剔除收缩压〈100mmHg、风心病及肥厚性心肌病病人后进行随机对照试验，厄贝沙坦治疗组（36例）在常规抗心力衰竭药物基础上加用厄贝沙坦，对照组（35例）原治疗不变，两组疗程均为12周。观察治疗前、后两组病人心功能、肾功能、超声心动图左室射血分数（LVEF）值，左室短轴缩短率和6min步行试验（6～MWT）的变化。结果：治疗12周后。两组心功能分级，6-MWT，超声心动图检查的LVEF与治疗前比较有明显改善（P〈0．05～〈0．01），且治疗组的显著优于对照组（P〈0．05～〈0．01）。结论：常规治疗联用厄贝沙坦对慢性心力衰竭患者，可进一步获得有益的疗效，并且有良好的安全性和耐受性。

Objective.. To study the therapeutic effect of irbesartan on patients with chronic heart failure （CHF）. Methods： The 71 CHF patients accepted anti-CHF therapy of whole dose （exclude patients with SBP〈100 mmHg, rheumatic heart disease and hypertrophic cardiomyopathy） were divided into therapy group （treated with irbesartan based routine anti-CHF therapy, 36 cases） and control group （treated with routine anti-CHF therapy, 35 cases）, therapeutic course was 12 weeks all. Results.. After therapy of weeks, the NYHA heart function, 6-minute walk test （6-MWT）, LVEF and fractional shortening of left ventricular brachyaxis of two groups significantly improved （P〈0.05-〈0.01）, but those of therapy group more improved （P〈0.05-0.01） compared ＇with control group. Conclusion： Irbesartan combine routine anti-CHF therapy may further and safely improve therapeutic effect of CHF patients.